Literature DB >> 28386722

Does pasireotide directly modulate skeletal muscle metabolism?

Federico Gatto1, Tullio Florio2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28386722     DOI： 10.1007/s12020-017-1291-8

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

1.  Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

Authors:  David L Kleinberg; Pietro Ameri; Baljit Singh
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

2.  Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Authors:  Renzo Cescato; Kimberly A Loesch; Beatrice Waser; Helmut R Mäcke; Jean E Rivier; Jean Claude Reubi; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2009-11-12

Review 3.  Metabolic comorbidities in Cushing's syndrome.

Authors:  Francesco Ferraù; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2015-06-09       Impact factor: 6.664

4.  Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

Authors:  Giovanni Tulipano; Lara Faggi; Stefan Schulz; Maurizio Spinello; Andrea Giustina
Journal:  Endocrine       Date:  2017-01-24       Impact factor: 3.633

Review 5.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

6.  Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.

Authors:  Alejandro Ibáñez-Costa; Esther Rivero-Cortés; Mari C Vázquez-Borrego; Manuel D Gahete; Luis Jiménez-Reina; Eva Venegas-Moreno; Andrés de la Riva; Miguel Ángel Arráez; Inmaculada González-Molero; Herbert A Schmid; Silvia Maraver-Selfa; Inmaculada Gavilán-Villarejo; Juan Antonio García-Arnés; Miguel A Japón; Alfonso Soto-Moreno; María A Gálvez; Raúl M Luque; Justo P Castaño
Journal:  J Endocrinol       Date:  2016-09-01       Impact factor: 4.286

7.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

Authors:  C Bruns; I Lewis; U Briner; G Meno-Tetang; G Weckbecker
Journal:  Eur J Endocrinol       Date:  2002-05       Impact factor: 6.664

Review 8.  Somatostatin receptors: from signaling to clinical practice.

Authors:  Marily Theodoropoulou; Günter K Stalla
Journal:  Front Neuroendocrinol       Date:  2013-07-18       Impact factor: 8.606

9.  Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

10.  Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.

Authors:  Siham Moatassim-Billah; Camille Duluc; Rémi Samain; Christine Jean; Aurélie Perraud; Emilie Decaup; Stéphanie Cassant-Sourdy; Youssef Bakri; Janick Selves; Herbert Schmid; Yvan Martineau; Muriel Mathonnet; Stéphane Pyronnet; Corinne Bousquet
Journal:  Oncotarget       Date:  2016-07-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.